162 related articles for article (PubMed ID: 23028037)
1. Genomic grade adds prognostic value in invasive lobular carcinoma.
Metzger-Filho O; Michiels S; Bertucci F; Catteau A; Salgado R; Galant C; Fumagalli D; Singhal SK; Desmedt C; Ignatiadis M; Haussy S; Finetti P; Birnbaum D; Saini KS; Berlière M; Veys I; de Azambuja E; Bozovic I; Peyro-Saint-Paul H; Larsimont D; Piccart M; Sotiriou C
Ann Oncol; 2013 Feb; 24(2):377-384. PubMed ID: 23028037
[TBL] [Abstract][Full Text] [Related]
2. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
3. Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
Reyal F; Bollet MA; Caly M; Gentien D; Carpentier S; Peyro-Saint-Paul H; Pierga JY; Cottu P; Dieras V; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X
PLoS One; 2012; 7(4):e35184. PubMed ID: 22529987
[TBL] [Abstract][Full Text] [Related]
4. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
5. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
Sestak I; Filipits M; Buus R; Rudas M; Balic M; Knauer M; Kronenwett R; Fitzal F; Cuzick J; Gnant M; Greil R; Dowsett M; Dubsky P
Clin Cancer Res; 2020 Sep; 26(17):4682-4687. PubMed ID: 32561662
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.
Tille JC; Vieira AF; Saint-Martin C; Djerroudi L; Furhmann L; Bidard FC; Kirova Y; Tardivon A; Reyal F; Carton M; Vincent-Salomon A
Mod Pathol; 2020 Nov; 33(11):2198-2207. PubMed ID: 32404955
[TBL] [Abstract][Full Text] [Related]
8. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
10. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
12. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
13. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
15. Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and Prognosis.
Liu YL; Choi C; Lee SM; Zhong X; Hibshoosh H; Kalinsky K; Connolly EP
Clin Breast Cancer; 2018 Apr; 18(2):114-120. PubMed ID: 28720418
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma.
Haque W; Arms A; Verma V; Hatch S; Brian Butler E; Teh BS
Breast; 2019 Feb; 43():67-73. PubMed ID: 30496936
[TBL] [Abstract][Full Text] [Related]
17. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
Mukhtar RA; Krings G; Chen YY; Mamounas ME; Fahrner-Scott K; Wong J; Alvarado M; Ewing C; Esserman LJ; Rugo H
Breast Cancer Res Treat; 2020 May; 181(1):23-29. PubMed ID: 32240457
[TBL] [Abstract][Full Text] [Related]
18. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
19. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]